Skip to main content

Advertisement

SpringerLink
Log in

HER2 status in a population-derived breast cancer cohort: discordances during tumor progression

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

This retrospective study investigates the correlation of intra-individual HER2 status between primary breast cancers and corresponding recurrences in a population derived cohort. The REMARK criteria were used as reference. In 151 breast cancer patients, primary tumors were analyzed for HER2 status on histopathology sections using immunohistochemistry (IHC) confirmed by fluorescence in situ hybridization (FISH) for IHC 2+ and 3+. Recurrences (loco regional and distant) were investigated by aspiration cytology, using HER2 immunocytochemistry (ICC) or FISH (ICC in 84 patients and FISH in 102 patients). In the 151 patients, sites of recurrence were bone/bone marrow 30%, liver 16%, local recurrence 18%, lung/pleura 10%, axillary lymph nodes 9%, skin (non-local) 7%, supra clavicular lymph nodes 5%, and other sites 7%. In 15 patients (10%) HER2 status changed, 7 of 108 patients (6%) from HER2 negative to HER2 positive and 8 of 43 (19%) from HER2 positive to HER2 negative. Intra-patient agreement in HER2 status was 76% (95% CI 64–87%), and the disagreement was 10% (95% CI 5–15%). The multivariable Cox analysis showed a significantly increased risk of dying in the patient group with changed HER2 status compared to patients with concordant positive HER2 status. Overall survival HR is 5.47 (95% CI 2.01–14.91) and survival from relapse HR is 3.22 (95% CI 1.18–8.77). The unstable status for HER2 in breast cancer is clinically significant and should motivate more frequent testing of recurrences.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ross SJ, Fletcher JA, Linette GP (2003) The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8:307–325

    Article  CAS  PubMed  Google Scholar 

  2. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235(4785):177–182

    Article  CAS  PubMed  Google Scholar 

  3. Slamon DJ, Leyland-Jones B, Shalk S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2/neu/NEU for metastatic breast cancer that overexpresses HER2/neu/NEU. N Engl J Med 44(11):783–792

    Article  Google Scholar 

  4. Marty M, Cognetti F, Maraninchi D et al (2001) Randomised phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor-2 positive metastatic breast cancer administered as first line treatment: the M77001 study group. J Clin Oncol 9: 4265–4274

    Google Scholar 

  5. Slamon D, Eiermann W, Robert N, Pienowski T, Martin M, Rolski J et al (2009) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study. SABCS (abstract 62)

  6. Ryden L, Haglund M, Bendahl P et al (2009) Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer—a national survey performed at pathology departments in Sweden. Acta Oncol 48:860–866

    PubMed  Google Scholar 

  7. MacFarlane R, Speers C, Masoudi H et al (2008) Molecular change in the primary breast cancer versus the relapsed/metastatic lesion from a large population based database and tissue micro array series. Proc Am Soc Clin Oncol 44:26 (abstract 1000)

    Google Scholar 

  8. Lower EE, Glass E (2009) Blau B HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 113:301–306

    Article  CAS  PubMed  Google Scholar 

  9. Liedtke C, Broglio K, Moulder S et al (2009) Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol (e-print)

  10. Meng S, Tripathy D, Shete S et al (2004) HER-2 gene amplification can be acquired as breast cancer progresses. PNAS 101(25):9393–9398

    Article  CAS  PubMed  Google Scholar 

  11. Yaziji H, Goldstein LC, Barry TS et al (2004) HER2 amplification ratios in breast cancer using parallel tissue based methods. JAMA 291:1972–1977

    Article  CAS  PubMed  Google Scholar 

  12. McShane L, Altman D, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23(36):9067–9072

    Article  PubMed  Google Scholar 

  13. Landis JR, Koch GG (1977) An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics 33(2):363–374

    Article  CAS  PubMed  Google Scholar 

  14. Schoenfeld D (1982) Partial residuals for the proportional hazards regression model. Biometrika 69:239–241

    Article  Google Scholar 

  15. Mittendorf E, Wu Y, Scaltriti M et al (2009) Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 15(23):7381–7388

    Article  CAS  PubMed  Google Scholar 

  16. Fehm T, Gebauer G, Jäger W (2002) Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients. Breast Cancer Res Treat 75(2):97–106

    Article  CAS  PubMed  Google Scholar 

  17. Pectasides D, Gaglia A (2006) HER2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy. Anticancer Res 26(1B):647–653

    CAS  PubMed  Google Scholar 

  18. Gancberg D, Di Leo A, Cardoso F et al (2002) Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13:1036–1043

    Article  CAS  PubMed  Google Scholar 

  19. Franco A, Col N (2004) Discordance in estrogen (ER) and progestin receptor (PR) status between primary metastatic breast cancer: a meta-analysis. In: Perry M (ed) 40th annual meeting of the ASCO, New Orleans, LA, 11 pp (abstract 539)

  20. Munzone E, Curigliano G, Rocca A et al (2006) Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res 8:R4

    Article  PubMed  Google Scholar 

  21. Lipton A, Leitzel K, Ali SM et al (2005) Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 104(2):257–263

    Article  CAS  PubMed  Google Scholar 

  22. Pauletti G, Danekar RongH et al (2000) Assessment of methods for tissues-based detection of the HER-2/neu alteration in human breast cancer: direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18(21):3651–3664

    CAS  PubMed  Google Scholar 

  23. Roche PC, Suman VJ, Jenkins RB et al (2002) Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94(11):855–857

    PubMed  Google Scholar 

  24. Wolf AC (2007) American society of clinical oncology/college of American pathologists guideline < recommendations for human epidermal growth receptor 2 testing in breast cancer. J Clin Oncol 25(1):118–145

    Article  Google Scholar 

  25. Wu JM, Fackler MJ, Halushka MK et al (2008) Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 14(7):1938–1946

    Article  CAS  PubMed  Google Scholar 

  26. Cottu PH, Asselah J, Lae M et al (2008) Intratumoral heterogeneity of HER-2/neu expression and its consequences for the management for advanced breast cancer. Ann Oncol 19:596–597

    Google Scholar 

  27. Andersson J, Linderholm B, Bergh J, Elmberger G (2004) HER-2/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components. Appl Immunohistochem Mol Morphol 12(1):14–20

    PubMed  Google Scholar 

  28. Ottesen G, Christensen J, Larsen J et al (2000) Carcinoma in situ of the breast: correlation of histopathology to immunohistochemical markers and DNA ploidy. Breast Cancer Res Treat 60(3):219–226

    Article  CAS  PubMed  Google Scholar 

  29. Norberg T, Klaar S, Kärf G, Nordgren H, Holmberg L, Bergh J (2001) Increased p53 mutation frequency during tumor progression—results from a breast cancer cohort. Cancer Res 61(22):8317–8321

    CAS  PubMed  Google Scholar 

  30. Shah SP, Morin RD, Khattra J et al (2009) Mutational evolution in a lobular breast cancer tumor profiled at single nucleotide resolution. Nature 461:809–913

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Jan Adolfsson and Ulla Johansson were supported by The Stockholm Regional Oncologic Centre. Nils Wilking was supported by The Local Breast Cancer Tumor Bank, Torsten Hägersten Karolinska Institutet. Jonas Bergh’s research group is supported by the grants from: The Swedish Cancer Society, The Stockholm Cancer Society, The King Gustav V Jubilee Fund, The Swedish Research Council, The Stockholm City Council, Karolinska Institutet and Stockholm County Council Research Strategy Committee, The Swedish Breast Cancer Association (BRO), Märit and Hans Rausing, and The Karolinska Institutet Research Funds.

Author information

Authors and Affiliations

  1. Department of Oncology-Pathology, Karolinska Institutet & Cancer Center Karolinska, 170 77, Stockholm, Sweden

    Ulla Wilking, Eva Karlsson, Lambert Skoog, Thomas Hatschek, Elisabet Lidbrink, Goran Elmberger, Hemming Johansson, Linda Lindström & Jonas Bergh

  2. Radiumhemmet, Karolinska University Hospital, Stockholm, Sweden

    Thomas Hatschek & Elisabet Lidbrink

  3. Department of Oncology, Karlstad Hospital, Karlstad, Sweden

    Eva Karlsson

  4. Manchester University at Paterson Institute, Christie Hospital, Manchester, UK

    Jonas Bergh

Authors
  1. Ulla Wilking
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eva Karlsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lambert Skoog
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas Hatschek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elisabet Lidbrink
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Goran Elmberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hemming Johansson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Linda Lindström
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jonas Bergh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulla Wilking.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wilking, U., Karlsson, E., Skoog, L. et al. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat 125, 553–561 (2011). https://doi.org/10.1007/s10549-010-1029-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-010-1029-2

Keywords

Search

Navigation